CD4 and neoplasm: Adding to the role of IL-17 as a tumor-promoting cytokine, Salazar Y. and colleagues demonstrated in humans that a high frequency of Th9 or Th17 among CD4+ T lymphocytes was significantly associated with decreased survival in NSCLC patients.